NASDAQ:ATHA Athira Pharma (ATHA) Stock Forecast, Price & News $3.02 +0.27 (+9.82%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.75▼$3.0250-Day Range$2.26▼$3.0452-Week Range$2.22▼$9.92Volume326,682 shsAverage Volume151,258 shsMarket Capitalization$114.61 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Athira Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside231.1% Upside$10.00 Price TargetShort InterestHealthy5.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 4 Articles This WeekInsider TradingAcquiring Shares$12,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($3.34) to ($3.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector237th out of 980 stocksBiological Products, Except Diagnostic Industry32nd out of 163 stocks 3.3 Analyst's Opinion Consensus RatingAthira Pharma has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Athira Pharma has a forecasted upside of 231.1% from its current price of $3.02.Amount of Analyst CoverageAthira Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.81% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Athira Pharma has recently decreased by 5.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHA. Previous Next 3.3 News and Social Media Coverage News SentimentAthira Pharma has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Athira Pharma this week, compared to 2 articles on an average week.Search Interest1 people have searched for ATHA on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders14.90% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.67% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Athira Pharma are expected to decrease in the coming year, from ($3.34) to ($3.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Athira Pharma (NASDAQ:ATHA) StockAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Read More Receive ATHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ATHA Stock News HeadlinesJune 1, 2023 | americanbankingnews.comAthira Pharma, Inc. (NASDAQ:ATHA) Short Interest UpdateMay 31, 2023 | finance.yahoo.comAthira Pharma to Participate in Upcoming June ConferencesJune 4, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 30, 2023 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Athira Pharma (ATHA)May 22, 2023 | markets.businessinsider.comAthira Pharma Names Andrew Gengos CFO - Quick FactsMay 22, 2023 | msn.comAthira Pharma gets new finance chiefMay 22, 2023 | finance.yahoo.comAthira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business OfficerMay 17, 2023 | markets.businessinsider.comAthira Pharma (ATHA) Receives a Hold from Stifel NicolausJune 4, 2023 | Legacy Research (Affiliate) (Ad)The “Amazon Secret Royalty Program” Can Help Anyone Retire Like RoyaltyA unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.May 17, 2023 | americanbankingnews.comAthira Pharma (NASDAQ:ATHA) Price Target Cut to $5.00 by Analysts at MizuhoMay 15, 2023 | msn.comMizuho Maintains Athira Pharma (ATHA) Buy RecommendationMay 12, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Athira Pharma (ATHA)May 12, 2023 | markets.businessinsider.comBTIG Sticks to Their Buy Rating for Athira Pharma (ATHA)May 11, 2023 | seekingalpha.comAthira Pharma GAAP EPS of -$0.19, revenue of $51.43MMay 11, 2023 | finance.yahoo.comAthira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business UpdatesMay 9, 2023 | americanbankingnews.comAthira Pharma (ATHA) to Release Earnings on WednesdayMay 8, 2023 | finance.yahoo.comAthira Pharma to Participate in Upcoming May Investor ConferencesMay 4, 2023 | nasdaq.comFour Biotech Stocks for ALS Awareness MonthApril 29, 2023 | finance.yahoo.comAthira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58%April 28, 2023 | americanbankingnews.comCritical Contrast: Exelixis (NASDAQ:EXEL) & Athira Pharma (NASDAQ:ATHA)April 25, 2023 | finance.yahoo.comAthira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual MeetingApril 22, 2023 | americanbankingnews.comShort Interest in Athira Pharma, Inc. (NASDAQ:ATHA) Rises By 8.4%April 11, 2023 | finance.yahoo.comAthira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual MeetingApril 4, 2023 | americanbankingnews.comBrokerages Set Athira Pharma, Inc. (NASDAQ:ATHA) Target Price at $14.80April 2, 2023 | finance.yahoo.comTrade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More SharesApril 2, 2023 | americanbankingnews.comInsider Buying: Athira Pharma, Inc. (NASDAQ:ATHA) Director Purchases 5,000 Shares of StockApril 2, 2023 | americanbankingnews.comBTIG Research Cuts Athira Pharma (NASDAQ:ATHA) Price Target to $10.00See More Headlines ATHA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHA Company Calendar Last Earnings3/23/2023Today6/04/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATHA CUSIPN/A CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees34Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+231.1%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-41.44% Return on Assets-38.78% Debt Debt-to-Equity RatioN/A Current Ratio9.57 Quick Ratio9.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.56 per share Price / Book0.54Miscellaneous Outstanding Shares37,950,000Free Float32,296,000Market Cap$114.61 million OptionableNot Optionable Beta2.82 Key ExecutivesDr. Mark J. Litton M.B.A. (Age 54)MBA, Ph.D., Pres, CEO & Director Comp: $726.32kMs. Rachel P. Lenington M.B.A.Chief Operating OfficerMr. Mark F. Worthington J.D.Gen. Counsel & Corp. Sec.Ms. Glenna K. Mileson (Age 63)Chief Financial Officer Mr. Robert RenningerDirector of Accounting & ReportingMs. Julie RathbunHead of Investor RelationsDr. Kevin Church Ph.D. (Age 37)Exec. VP of Research More ExecutivesKey CompetitorsOcugenNASDAQ:OCGNCellectisNASDAQ:CLLSElevation OncologyNASDAQ:ELEVJounce TherapeuticsNASDAQ:JNCETalaris TherapeuticsNASDAQ:TALSView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCSold 19,765 shares on 6/1/2023Ownership: 0.113%Ameriprise Financial Inc.Sold 22,911 shares on 5/22/2023Ownership: 0.031%JPMorgan Chase & Co.Bought 6,542 shares on 5/18/2023Ownership: 0.071%Geode Capital Management LLCBought 29,795 shares on 5/16/2023Ownership: 1.667%Susquehanna International Group LLPBought 6,700 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ATHA Stock - Frequently Asked Questions Should I buy or sell Athira Pharma stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athira Pharma in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATHA shares. View ATHA analyst ratings or view top-rated stocks. What is Athira Pharma's stock price forecast for 2023? 5 equities research analysts have issued 12-month price targets for Athira Pharma's stock. Their ATHA share price forecasts range from $5.00 to $20.00. On average, they expect the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 231.1% from the stock's current price. View analysts price targets for ATHA or view top-rated stocks among Wall Street analysts. How have ATHA shares performed in 2023? Athira Pharma's stock was trading at $3.17 at the start of the year. Since then, ATHA shares have decreased by 4.7% and is now trading at $3.02. View the best growth stocks for 2023 here. Are investors shorting Athira Pharma? Athira Pharma saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 2,050,000 shares, a decrease of 5.5% from the April 30th total of 2,170,000 shares. Based on an average trading volume of 214,500 shares, the short-interest ratio is currently 9.6 days. Approximately 5.8% of the company's stock are sold short. View Athira Pharma's Short Interest. When is Athira Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our ATHA earnings forecast. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:ATHA) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.09. What ETFs hold Athira Pharma's stock? ETFs with the largest weight of Athira Pharma (NASDAQ:ATHA) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN). What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athira Pharma investors own include GW Pharmaceuticals (GWPH), Intel (INTC), Lumentum (LITE), NIO (NIO), NVIDIA (NVDA), Boeing (BA), Alibaba Group (BABA), Beyond Meat (BYND), Delta Air Lines (DAL) and Extreme Networks (EXTR). When did Athira Pharma IPO? (ATHA) raised $160 million in an initial public offering (IPO) on Friday, September 18th 2020. The company issued 10,000,000 shares at $15.00-$17.00 per share. Goldman Sachs, Jefferies and Stifel acted as the underwriters for the IPO and JMP Securities was co-manager. What is Athira Pharma's stock symbol? Athira Pharma trades on the NASDAQ under the ticker symbol "ATHA." Who are Athira Pharma's major shareholders? Athira Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (6.19%), BlackRock Inc. (5.99%), BML Capital Management LLC (4.92%), Simplify Asset Management Inc. (3.66%), Geode Capital Management LLC (1.67%) and Two Sigma Advisers LP (1.30%). Insiders that own company stock include Glenna Mileson, Hans Moebius, James A Johnson, Joseph Edelman, Kelly A Romano, Mark James Litton, Mark Worthington, Perceptive Advisors Llc and Rachel Lenington. View institutional ownership trends. How do I buy shares of Athira Pharma? Shares of ATHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Athira Pharma's stock price today? One share of ATHA stock can currently be purchased for approximately $3.02. How much money does Athira Pharma make? Athira Pharma (NASDAQ:ATHA) has a market capitalization of $114.61 million. The company earns $-95,640,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis. How can I contact Athira Pharma? The official website for the company is athira.com. The company can be reached via phone at 425-620-8501 or via email at ir@athira.com. This page (NASDAQ:ATHA) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.